NDA 022567 · Abbvie
Viibryd
Vilazodone Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Apr 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Jan 21, 2011
Approved uses
3
Original approval plus efficacy supplements
Registered trials
33
12 Phase 3, 1 recruiting
FAERS reports
9,233
3,618 serious, 188 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavi ors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . V IIBRYD is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients ( 5.1 ). Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Viibryd is not approved for use in pediatric patients ( 8.4 ).
What it is approved for
From the label in effect Oct 1, 2023.
VIIBRYD ® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. VIIBRYD is indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ).
Mechanism: The mechanism of action of vilazodone in the treatment of major depressive disorder is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT 1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone’s antidepressant effect are unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 31, 2020 Supplement 21 · Efficacy · priority review LabelLetter
- Mar 16, 2015 Supplement 12 · Efficacy LetterLabel
- Jan 21, 2011 Original approval · Type 1 - New Molecular Entity NovelLabelPediatric Written RequestPediatric Amendment 1
3 products under this application
- VIIBRYD · VILAZODONE HYDROCHLORIDE 10MG · TABLET, ORAL · Prescription · TE AB
- VIIBRYD · VILAZODONE HYDROCHLORIDE 20MG · TABLET, ORAL · Prescription · TE AB
- VIIBRYD · VILAZODONE HYDROCHLORIDE 40MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Vilazodone" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of Vilazodone in Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01573598 · 1,219 participants · Start Apr 2012 · Primary completion Oct 2014
Drug: Placebo; Vilazodone and 1 more · For: Major Depressive Disorder
Sites: Beverly Hills, California; Chino, California; Costa Mesa, California · 75 sites in all
- Safety and Efficacy of Vilazodone in Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01473381 · 1,162 participants · Start Dec 2011 · Primary completion Jun 2013
Drug: Vilazodone; Placebo to citalopram and 2 more · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Dothan, Alabama; Scottsdale, Arizona · 54 sites in all
- Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01715805 · 1,022 participants · Start Nov 15, 2012 · Primary completion Jun 24, 2016
Drug: Cariprazine; Placebo and 1 more · For: Major Depressive Disorder
Sites: Tucson, Arizona; Little Rock, Arkansas; Cerritos, California · 85 sites in all
- Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01469377 · 819 participants · Start Dec 15, 2011 · Primary completion Dec 12, 2013
Drug: Placebo; Cariprazine · For: Major Depressive Disorder
Sites: Garden Grove, California; National City, California; Oceanside, California · 72 sites in all
- Department of Defense PTSD Adaptive Platform Trial - Master ProtocolPivotal-lookingSuspended
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT05422612 · 800 participants (planned) · Start Nov 2, 2023 · Primary completion Jul 2028
Drug: Intervention A Fluoxetine Hydrochloride (HCl); Intervention A Placebo and 6 more · For: Post Traumatic Stress Disorder
Sites: Miami, Florida; Atlanta, Georgia; Tripler AMC, Hawaii · 9 sites in all
- Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01629966 · 680 participants · Start Jun 30, 2012 · Primary completion Feb 28, 2014
Drug: Placebo; Vilazodone and 1 more · For: Generalized Anxiety Disorder
Sites: Birmingham, Alabama; Beverly Hills, California; Glendale, California · 37 sites in all
- A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00644358 · 616 participants · Start Dec 31, 2007 · Primary completion May 31, 2009
Drug: vilazodone · For: Major Depressive Disorder
Sites: Garden Grove, California; San Diego, California; Torrance, California · 38 sites in all
- Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01878292 · 529 participants · Start Jul 11, 2013 · Primary completion Mar 17, 2016
Drug: Placebo; Vilazodone and 1 more · For: Major Depressive Disorder
Sites: Imperial, California; Los Angeles, California; Murrieta, California · 52 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,096
- nausea786
- diarrhoea783
- anxiety635
- insomnia620
- drug ineffective566
- headache544
- depression492
- dizziness485
- fatigue463
- suicidal ideation417
- feeling abnormal402
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2011 | 460 |
| 2012 | 1,132 |
| 2013 | 738 |
| 2014 | 524 |
| 2015 | 444 |
| 2016 | 880 |
| 2017 | 736 |
| 2018 | 562 |
| 2019 | 743 |
| 2020 | 829 |
| 2021 | 562 |
| 2022 | 484 |
| 2023 | 380 |
| 2024 | 296 |
| 2025 | 279 |
| 2026 | 183 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Viibryd (Vilazodone HCl)
2024 spending
$6.0M
Beneficiaries
3,238
13,120 claims
Per beneficiary
$1,848
$11.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $125,109,998 |
| 2021 | $134,672,680 |
| 2022 | $86,482,099 |
| 2023 | $17,377,041 |
| 2024 | $5,984,796 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE, McKenzie JE, Bailey AP, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
Zhou X, Teng T, Zhang Y, et al. · Lancet Psychiatry 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Vilazodone poisoning: a systematic review.
Baumgartner K, Doering M, Schwarz E · Clin Toxicol (Phila) 2020 · Systematic Review
- Comparative efficacy of antidepressant medication for adolescent depression: a network meta-analysis and systematic review.
Wu T, Song F, Cao W, et al. · BMC Psychiatry 2025 · Systematic Review, Comparative Study
- Probiotics for adults with major depressive disorder compared with antidepressants: a systematic review and network meta-analysis.
Zhao S, Liang S, Tao J, et al. · Nutr Rev 2025 · Systematic Review, Comparative Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.